MUC1-Specific Cytotoxic T Lymphocytes in Cancer Therapy: Induction and Challenge

Table 2

MUC1-based immunotherapy trials.

Author	Strategy	Clinical trial phase	Major observation	Cancer type
Apostolopouls et al. [57]	Oxidized Mannan-MUC1	III	Breast cancer recurrence prevention	Breast
Ramlau et al. [58]	TG4010	II	TG4010 can be coupled with chemotherapy	Lung
Dreicer et al. [59]	TG4010	II	Increased PSA doubling time	Prostate
Oudard et al. [60]	TG4010	II	MUC1 T cell responses	RCC
Quoix et al. [61]	TG4010	IIB	Improved survival	Lung
Ohyanagi et al. [62]	BLP25	I/II	Well tolerated, low side effects	Lung
Butts et al. [63]	BLP25	II/B	Increased survival	Lung
WU et al. [64]	BLP25	III inspire	In progress/increased survival	Lung
Butts et al. [65]	BLP25	I/II	New formulation well tolerated	Lung
Wright et al. [66]	MUC1 TIL Transfers	I/II	Influence of the tumor burden on adoptive transfer of MUC1 specific T cells	Breast
Lepisto et al. [67]	Dendritic cells pulsed with MUC1	I/II	Well tolerated, induction of T cell responses	Pancreas
Kondo et al. [68]	Dendritic cells and CTL transfer	I	Clinical response	Pancreas
Dobrzanski et al. [69]	Adoptive transfer CD4 T cells plus IL-10	I	Clinical response	Ovarian
Mohebtash et al. [70]	PANVAC-VF	II	Clinical effects	Breast/ovary
Ibrahim et al. [71]	AS1402 + Letrosole	II	Use of Letrosole uncompatible with AS1402 strategy	Breast
Pegram et al. [72]	AS1402	I	Well tolerated, need phase II to evaluate efficacy	Breast
Rittig et al. [73]	ARN muc1	I/II	Induction of CD4+ T cell responses	RCC